Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets    
Cash and cash equivalents $ 145,326 $ 158,779
Short-term deposits   22,694
Marketable securities - available for sale debt securities 86,532  
Accounts receivable, net of allowance for doubtful accounts of $0 and $0 4,063 1,480
Other current assets and prepaid expenses (including current portion of clinical materials) 17,983 15,798
Total current assets 253,904 198,751
Restricted cash 4,232 4,017
Clinical materials 2,096 2,580
Property, plant and equipment, net 39,771 27,899
Intangibles, net 1,374 1,268
Total assets 301,377 234,515
Current liabilities    
Accounts payable (including amounts due to related parties of $00 and $326) 2,489 11,350
Accrued expenses and other accrued liabilities (including amounts due to related parties of $1 and $39) 23,491 17,528
Deferred revenue 42,592 11,392
Total current liabilities 68,572 40,270
Deferred revenue, non-current   24,962
Other liabilities, non-current 3,820 3,141
Total liabilities 72,392 68,373
Contingencies and commitments - Note 9
Stockholders' equity    
Common stock - Ordinary shares par value GBP 0.001, 701,103,126 authorized and 562,119,334 issued and outstanding (2016: 574,711,900 authorized and 424,775,092 issued and outstanding) 854 683
Additional paid in capital 452,553 341,200
Accumulated other comprehensive loss (20,055) (14,249)
Accumulated deficit (204,367) (161,492)
Total stockholders' equity 228,985 166,142
Total liabilities and stockholders' equity $ 301,377 $ 234,515